



# MATERIAL SAFETY DATA SHEET

Revision date: 14-Mar-2007

Version: 2.0

Page 1 of 6

## 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

**Pfizer Inc**  
**Pfizer Pharmaceuticals Group**  
235 East 42nd Street  
New York, New York 10017  
1-212-573-2222

**Pfizer Ltd**  
Ramsgate Road  
Sandwich, Kent  
CT13 9NJ  
United Kingdom  
+00 44 (0)1304 616161

**Emergency telephone number:**  
CHEMTREC (24 hours): 1-800-424-9300

**Emergency telephone number:**  
ChemSafe (24 hours): +44 (0)208 762 8322

**Material Name: Somatropin Powder for Solution for Injection (1.5 mg)**

**Trade Name:** Genotropin®  
**Synonyms:** Human Growth Hormone; HGH; Somatotropin  
**Chemical Family:** Mixture  
**Intended Use:** Pharmaceutical product for the treatment of human growth hormone deficiency.

## 2. COMPOSITION/INFORMATION ON INGREDIENTS

### Hazardous

Ingredient	CAS Number	EU EINECS List	%
Somatropin	12629-01-5	235-735-8	5

Ingredient	CAS Number	EU EINECS List	%
Dibasic Potassium Phosphate	7758-11-4	231-834-5	*
Glycine	56-40-6	200-272-2	*
Sodium phosphate, dibasic	7558-79-4	231-448-7	*
Water	7732-18-5	231-791-2	*

**Additional Information:** \* Proprietary  
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

## 3. HAZARDS IDENTIFICATION

**Appearance:** White sterile lyophilized powder plus sterile diluent  
**Signal Word:** DANGER

**Statement of Hazard:** Toxic if swallowed.  
May cause allergic skin reaction.  
Suspected of damaging fertility or the unborn child.

**Additional Hazard Information:**  
**Long Term:** Animal studies indicate that this material may cause adverse effects on the blood, kidneys, liver, mammary gland.

**Known Clinical Effects:** Adverse effects associated with the therapeutic use include glucose intolerance, fluid retention, headache and effects on the thyroid. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Drugs of this class may cause formation of antibodies.

## MATERIAL SAFETY DATA SHEET

Material Name: Somatropin Powder for Solution for Injection  
(1.5 mg)

Revision date: 14-Mar-2007

Page 2 of 6

Version: 2.0

**EU Indication of danger:** Irritant  
Toxic to Reproduction; Category 3

**EU Hazard Symbols:**



**EU Risk Phrases:** R43 - May cause sensitization by skin contact.  
R62 - Possible risk of impaired fertility.  
R63 - Possible risk of harm to the unborn child.  
**Australian Hazard Classification (NOHSC):** Hazardous Substance. Non-Dangerous Goods.

**Note:** This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### 4. FIRST AID MEASURES

**Eye Contact:** Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical attention.

**Skin Contact:** Remove clothing and wash affected skin with soap and water. If irritation occurs or persists, get medical attention.

**Ingestion:** Get medical attention. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.

**Inhalation:** Remove to fresh air. If not breathing, give artificial respiration. Get medical attention.

### 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

**Hazardous Combustion Products:** No data available

**Fire Fighting Procedures:** During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

**Fire / Explosion Hazards:** Not available

### 6. ACCIDENTAL RELEASE MEASURES

**Health and Safety Precautions:** Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

## MATERIAL SAFETY DATA SHEET

Material Name: Somatropin Powder for Solution for Injection  
(1.5 mg)

Page 3 of 6

Revision date: 14-Mar-2007

Version: 2.0

### Measures for Environmental Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### Additional Consideration for Large Spills:

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

## 7. HANDLING AND STORAGE

### General Handling:

Minimize dust generation and accumulation. Avoid breathing dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling.

### Storage Conditions:

Store as directed by product packaging.

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

### Somatropin

#### Pfizer OEL TWA-8 Hr:

10ug/m<sup>3</sup>, Sensitizer

The exposure limit(s) listed for solid components are only relevant if dust or mist may be generated.

### Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

### Personal Protective Equipment:

#### Hands:

Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

#### Eyes:

Wear safety glasses or goggles if eye contact is possible.

#### Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

#### Respiratory protection:

If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

## 9. PHYSICAL AND CHEMICAL PROPERTIES:

### Physical State:

Lyophilized powder plus sterile diluent

### Color:

White

### Molecular Formula:

Mixture

### Molecular Weight:

Mixture

## 10. STABILITY AND REACTIVITY

### Stability:

Stable under normal conditions of use.

### Conditions to Avoid:

No data available

### Incompatible Materials:

None identified

## 11. TOXICOLOGICAL INFORMATION

### General Information:

The information included in this section describes the potential hazards of the individual ingredients.

## MATERIAL SAFETY DATA SHEET

Material Name: Somatropin Powder for Solution for Injection  
(1.5 mg)

Page 4 of 6

Revision date: 14-Mar-2007

Version: 2.0

### Acute Toxicity: (Species, Route, End Point, Dose)

#### **Somatropin**

Rat Oral LD50 242 mg/kg  
Rat Dermal LD50 1100 mg/kg  
Rat Inhalation LC50 1h 710 mg/m<sup>3</sup>  
Mouse Oral LD50 828 mg/kg  
Mouse Intraperitoneal LD50 828 mg/kg

#### **Glycine**

Rat Oral LD 50 7930 mg/kg  
Mouse Oral LD 50 4920 mg/kg

### Irritation / Sensitization: (Study Type, Species, Severity)

#### **Sodium phosphate, dibasic**

Eye Irritation Rabbit Mild  
Skin Irritation Rabbit Mild

#### **Somatropin**

Skin Irritation Rabbit Negative  
Not specified Guinea Pig Positive  
Antigenicity- Active anaphylaxis Guinea Pig Positive  
Antigenicity- Passive cutaneous anaphylaxis Guinea Pig Positive

### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

#### **Somatropin**

1 Month(s) Rat Intramuscular 0.63 mg/kg/day NOAEL Mammary gland  
3 Month(s) Rat Subcutaneous 0.37 mg/kg/day LOAEL Liver, Adrenal gland, Kidney  
3 Month(s) Monkey Subcutaneous 0.125 mg/kg/day LOAEL Mammary gland, Blood  
52 Week(s) Monkey Subcutaneous 0.63 mg/kg/day NOAEL Adipose tissue, Mammary gland, Reproductive system

### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

#### **Somatropin**

Embryo / Fetal Development Rat Subcutaneous 3.3 mg/kg/day NOAEL Not teratogenic  
Embryo / Fetal Development Rabbit Intramuscular 0.3 mg/kg/day NOAEL Not Teratogenic  
Embryo / Fetal Development Rat Subcutaneous 3.3 mg/kg/day LOAEL Fetotoxicity  
Reproductive & Fertility Rat Subcutaneous 0.3 mg/kg/day NOAEL Fertility  
Peri-/Postnatal Development Rat Subcutaneous 3.3 mg/kg/day NOAEL No effects at maximum dose

### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

#### **Somatropin**

Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative  
*In Vitro* Mammalian Cell Mutagenicity Mouse Lymphoma Negative  
*In Vivo* Chromosome Aberration Rat Bone Marrow Negative  
*In Vitro* Chromosome Aberration Human Lymphocytes Negative

### **Carcinogen Status:**

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

## MATERIAL SAFETY DATA SHEET

Material Name: Somatropin Powder for Solution for Injection  
(1.5 mg)

Page 5 of 6

Revision date: 14-Mar-2007

Version: 2.0

### 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been investigated. Releases to the environment should be avoided.

### 13. DISPOSAL CONSIDERATIONS

**Disposal Procedures:** Dispose of waste in accordance with all applicable laws and regulations.

### 14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

### 15. REGULATORY INFORMATION

**EU Symbol:** Xn  
**EU Indication of danger:** Irritant  
Toxic to Reproduction; Category 3

**EU Risk Phrases:**  
R43 - May cause sensitization by skin contact.  
R62 - Possible risk of impaired fertility.  
R63 - Possible risk of harm to the unborn child.

**EU Safety Phrases:**  
S36/37 - Wear suitable protective clothing and gloves.  
S53 - Avoid exposure - obtain special instructions before use.

**OSHA Label:**  
DANGER  
Toxic if swallowed.  
May cause allergic skin reaction.  
Suspected of damaging fertility or the unborn child.

#### Canada - WHMIS: Classifications

**WHMIS hazard class:**  
D1b toxic materials  
D2a very toxic materials  
D2b toxic materials

# MATERIAL SAFETY DATA SHEET

Material Name: Somatropin Powder for Solution for Injection  
(1.5 mg)  
Revision date: 14-Mar-2007

Page 6 of 6

Version: 2.0



## Dibasic Potassium Phosphate

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS List	231-834-5

## Glycine

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS List	200-272-2

## Somatropin

Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS List	235-735-8

## Sodium phosphate, dibasic

CERCLA/SARA Hazardous Substances and their Reportable Quantities:	= 2270 kg final RQ = 5000 lb final RQ
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS List	231-448-7

## Water

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS List	231-791-2

## 16. OTHER INFORMATION

### Reasons for Revision:

Updated Section 3 - Hazard Identification. Updated Section 7 - Handling and Storage. Added Pfizer OEL (Section 8). Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 14 - Transport Information. Updated Section 15 - Regulatory Information.

### Prepared by:

Toxicology and Hazard Communication  
Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

End of Safety Data Sheet